由gp41序列ELDKWAS诱导产生的针对不同1型人类免疫缺陷病毒分离株的交叉中和活性。
Cross-neutralizing activity against divergent human immunodeficiency virus type 1 isolates induced by the gp41 sequence ELDKWAS.
作者信息
Muster T, Guinea R, Trkola A, Purtscher M, Klima A, Steindl F, Palese P, Katinger H
机构信息
Institut für Angewandte Mikrobiologie, Universität für Bodenkultur, Vienna, Austria.
出版信息
J Virol. 1994 Jun;68(6):4031-4. doi: 10.1128/JVI.68.6.4031-4034.1994.
Abstract
Previously we identified the highly conserved amino acids Glu-Leu-Asp-Lys-Trp-Ala (ELDKWA) on the ecto-domain of gp41 as the epitope of a neutralizing monoclonal antibody (2F5) directed against human immunodeficiency virus type 1. In the present study, the sequence defining the epitope was introduced into the loop of antigenic site B of the influenza virus hemagglutinin. The resulting chimeric virus was able to elicit ELDKWA-specific immunoglobulins G and A in antisera of mice. Moreover, the distantly related human immunodeficiency virus type 1 isolates MN, RF, and IIIB were neutralized by these antisera. These data suggest that this conserved B-cell epitope is a promising candidate for inclusion in a vaccine against AIDS. The results also show that influenza virus can be used to effectively present the antigenic structure of this B-cell epitope.
摘要
此前，我们将gp41胞外结构域上高度保守的氨基酸序列Glu-Leu-Asp-Lys-Trp-Ala（ELDKWA）鉴定为一种针对1型人类免疫缺陷病毒的中和单克隆抗体（2F5）的表位。在本研究中，将确定该表位的序列引入流感病毒血凝素抗原位点B的环中。所得嵌合病毒能够在小鼠抗血清中引发针对ELDKWA的免疫球蛋白G和A。此外，这些抗血清可中和亲缘关系较远的1型人类免疫缺陷病毒分离株MN、RF和IIIB。这些数据表明，这个保守的B细胞表位有望成为艾滋病疫苗的组成部分。结果还表明，流感病毒可用于有效呈递该B细胞表位的抗原结构。
相似文献
1
Cross-neutralizing activity against divergent human immunodeficiency virus type 1 isolates induced by the gp41 sequence ELDKWAS.由gp41序列ELDKWAS诱导产生的针对不同1型人类免疫缺陷病毒分离株的交叉中和活性。
J Virol. 1994 Jun;68(6):4031-4. doi: 10.1128/JVI.68.6.4031-4034.1994.
2
A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1.人类免疫缺陷病毒1型gp41上一个保守的中和表位。
J Virol. 1993 Nov;67(11):6642-7. doi: 10.1128/JVI.67.11.6642-6647.1993.
3
Immunogenic presentation of a conserved gp41 epitope of human immunodeficiency virus type 1 on recombinant surface antigen of hepatitis B virus.1型人类免疫缺陷病毒保守gp41表位在重组乙型肝炎病毒表面抗原上的免疫原性呈递
J Gen Virol. 1996 Sep;77 ( Pt 9):2001-8. doi: 10.1099/0022-1317-77-9-2001.
4
ELNKWA-epitope specific antibodies induced by epitope-vaccine recognize ELDKWA- and other two neutralizing-resistant mutated epitopes on HIV-1 gp41.表位疫苗诱导产生的ELNKWA表位特异性抗体可识别HIV-1 gp41上的ELDKWA以及其他两个抗中和突变表位。
Immunol Lett. 2001 Jan 1;75(2):149-52. doi: 10.1016/s0165-2478(00)00298-4.
5
A broadly neutralizing human monoclonal antibody against gp41 of human immunodeficiency virus type 1.一种针对1型人类免疫缺陷病毒gp41的广泛中和性人源单克隆抗体。
AIDS Res Hum Retroviruses. 1994 Dec;10(12):1651-8. doi: 10.1089/aid.1994.10.1651.
6
Neutralization of divergent human immunodeficiency virus type 1 variants and primary isolates by IAM-41-2F5, an anti-gp41 human monoclonal antibody.抗gp41人单克隆抗体IAM-41-2F5对不同的1型人类免疫缺陷病毒变体和原代分离株的中和作用
Proc Natl Acad Sci U S A. 1994 Apr 12;91(8):3348-52. doi: 10.1073/pnas.91.8.3348.
7
Immunogenic and antigenic dominance of a nonneutralizing epitope over a highly conserved neutralizing epitope in the gp41 envelope glycoprotein of human immunodeficiency virus type 1: its deletion leads to a strong neutralizing response.人免疫缺陷病毒1型gp41包膜糖蛋白中一个非中和表位相对于高度保守的中和表位的免疫原性和抗原优势：其缺失导致强烈的中和反应。
Virology. 2000 Jan 5;266(1):66-78. doi: 10.1006/viro.1999.0041.
8
HIV-1 vaccine development: constrained peptide immunogens show improved binding to the anti-HIV-1 gp41 MAb.HIV-1疫苗研发：受限肽免疫原显示出与抗HIV-1 gp41单克隆抗体的结合能力有所提高。
Biochemistry. 2003 Mar 25;42(11):3214-23. doi: 10.1021/bi026952u.
9
Crystal structure of the complex between the F(ab)' fragment of the cross-neutralizing anti-HIV-1 antibody 2F5 and the F(ab) fragment of its anti-idiotypic antibody 3H6.交叉中和抗HIV-1抗体2F5的F(ab)'片段与其抗独特型抗体3H6的F(ab)片段之间复合物的晶体结构。
J Mol Biol. 2008 Oct 17;382(4):910-9. doi: 10.1016/j.jmb.2008.07.057. Epub 2008 Jul 27.
10
A predefined epitope-specific monoclonal antibody recognizes ELDEWA-epitope just presenting on gp41 of HIV-1 O clade.一种预先定义的表位特异性单克隆抗体识别仅存在于HIV-1 O亚型gp41上的ELDEWA表位。
Immunol Lett. 2002 Dec 3;84(3):205-9. doi: 10.1016/s0165-2478(02)00174-8.
引用本文的文献
1
Vaccine induction of heterologous HIV-1-neutralizing antibody B cell lineages in humans.人体中疫苗诱导的异源 HIV-1 中和抗体 B 细胞谱系。
Cell. 2024 Jun 6;187(12):2919-2934.e20. doi: 10.1016/j.cell.2024.04.033. Epub 2024 May 17.
2
Antibody-directed evolution reveals a mechanism for enhanced neutralization at the HIV-1 fusion peptide site.抗体定向进化揭示了 HIV-1 融合肽位点增强中和的机制。
Nat Commun. 2023 Nov 21;14(1):7593. doi: 10.1038/s41467-023-42098-5.
3
Identification of Anti-gp41 Monoclonal Antibodies That Effectively Target Cytotoxic Immunoconjugates to Cells Infected with Human Immunodeficiency Virus, Type 1.鉴定能有效将细胞毒性免疫偶联物靶向到1型人类免疫缺陷病毒感染细胞的抗gp41单克隆抗体。
Vaccines (Basel). 2023 Apr 12;11(4):829. doi: 10.3390/vaccines11040829.
4
Adjuvants influence the maturation of VRC01-like antibodies during immunization.佐剂在免疫过程中影响VRC01样抗体的成熟。
iScience. 2022 Nov 2;25(11):105473. doi: 10.1016/j.isci.2022.105473. eCollection 2022 Nov 18.
5
Contribution to HIV Prevention and Treatment by Antibody-Mediated Effector Function and Advances in Broadly Neutralizing Antibody Delivery by Vectored Immunoprophylaxis.抗体介导的效应功能对 HIV 预防和治疗的贡献以及通过载体免疫预防广泛中和抗体传递的进展。
Front Immunol. 2021 Sep 15;12:734304. doi: 10.3389/fimmu.2021.734304. eCollection 2021.
6
Mucosal Priming with a Recombinant Influenza A Virus-Vectored Vaccine Elicits T-Cell and Antibody Responses to HIV-1 in Mice.黏膜佐剂增强的重组流感病毒载体疫苗在小鼠中诱导针对 HIV-1 的 T 细胞和抗体应答。
J Virol. 2021 May 24;95(12). doi: 10.1128/JVI.00059-21.
7
The CH1α domain of mucosal gp41 IgA contributes to antibody specificity and antiviral functions in HIV-1 highly exposed Sero-Negative individuals.黏膜 gp41 IgA 的 CH1α 结构域有助于 HIV-1 高度暴露的血清阴性个体中的抗体特异性和抗病毒功能。
PLoS Pathog. 2020 Dec 14;16(12):e1009103. doi: 10.1371/journal.ppat.1009103. eCollection 2020 Dec.
8
Neutralizing Antibodies Targeting HIV-1 gp41.靶向 HIV-1 gp41 的中和抗体。
Viruses. 2020 Oct 23;12(11):1210. doi: 10.3390/v12111210.
9
Gp41-targeted antibodies restore infectivity of a fusion-deficient HIV-1 envelope glycoprotein.靶向 gp41 的抗体恢复了融合缺陷型 HIV-1 包膜糖蛋白的感染性。
PLoS Pathog. 2020 May 11;16(5):e1008577. doi: 10.1371/journal.ppat.1008577. eCollection 2020 May.
10
An Influenza Virus Hemagglutinin-Based Vaccine Platform Enables the Generation of Epitope Specific Human Cytomegalovirus Antibodies.基于流感病毒血凝素的疫苗平台可产生表位特异性人巨细胞病毒抗体。
Vaccines (Basel). 2019 Jun 14;7(2):51. doi: 10.3390/vaccines7020051.
本文引用的文献
1
Construction of an HIV-1 peptide vaccine containing a multideterminant helper peptide linked to a V3 loop peptide 18 inducing strong neutralizing antibody responses in mice of multiple MHC haplotypes after two immunizations.构建一种HIV-1肽疫苗，该疫苗包含与V3环肽18相连的多决定簇辅助肽，经两次免疫后在多种MHC单倍型小鼠中诱导强烈的中和抗体反应。
J Immunol. 1993 Jun 15;150(12):5647-65.
2
Chimeric influenza virus induces neutralizing antibodies and cytotoxic T cells against human immunodeficiency virus type 1.嵌合流感病毒诱导产生针对1型人类免疫缺陷病毒的中和抗体和细胞毒性T细胞。
J Virol. 1993 Nov;67(11):6659-66. doi: 10.1128/JVI.67.11.6659-6666.1993.
3
A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1.人类免疫缺陷病毒1型gp41上一个保守的中和表位。
J Virol. 1993 Nov;67(11):6642-7. doi: 10.1128/JVI.67.11.6642-6647.1993.
4
Generation of human monoclonal antibodies against HIV-1 proteins; electrofusion and Epstein-Barr virus transformation for peripheral blood lymphocyte immortalization.抗HIV-1蛋白人单克隆抗体的产生；用于外周血淋巴细胞永生化的电融合和EB病毒转化
AIDS Res Hum Retroviruses. 1994 Apr;10(4):359-69. doi: 10.1089/aid.1994.10.359.
5
6
Antisera raised against the second variable region of the external envelope glycoprotein of human immunodeficiency virus type 1 cross-neutralize and show an increased neutralization index when they act together with antisera to the V3 neutralization epitope.针对人类免疫缺陷病毒1型外膜糖蛋白第二个可变区产生的抗血清具有交叉中和作用，并且当它们与针对V3中和表位的抗血清共同作用时，中和指数会增加。
J Gen Virol. 1993 Dec;74 ( Pt 12):2609-17. doi: 10.1099/0022-1317-74-12-2609.
7
Complete sequence analysis shows that the hemagglutinins of the H0 and H2 subtypes of human influenza virus are closely related.完整的序列分析表明，人流感病毒H0和H2亚型的血凝素密切相关。
Virology. 1981 May;111(1):113-24. doi: 10.1016/0042-6822(81)90658-9.
8
In vitro generation of an HTLV-III variant by neutralizing antibody.通过中和抗体在体外产生HTLV-III变体。
J Immunol. 1986 Nov 15;137(10):3306-9.
9
Type-restricted neutralization of molecular clones of human immunodeficiency virus.人免疫缺陷病毒分子克隆的型特异性中和作用
Science. 1988 Jul 15;241(4863):357-9. doi: 10.1126/science.3388046.
10
Generation of a neutralization-resistant variant of HIV-1 is due to selection for a point mutation in the envelope gene.HIV-1中和抗性变异体的产生是由于包膜基因中一个点突变的选择。
Cell. 1988 Jul 1;54(1):57-63. doi: 10.1016/0092-8674(88)90179-1.
Zotero 插件